CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea, according to a landmark meta-analysis supported by Resmed and published in The Lancet Respiratory Medicine ...
Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.
ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.
Investor's Business Daily on MSN10d
ResMed Among Top Stocks For Recent And Long-Term Profit GrowthResMed showed 29% EPS growth last quarter. Sales gains came in at 10%. ResMed earns the No. 6 rank among its peers in the ...
Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey ...
ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the ...
“For people with OSA, using CPAP versus not using CPAP can literally be a matter of life or death,” said Carlos Nunez, M.D., Resmed’s Chief Medical Officer. “Decades of research have shown CPAP can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback